Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT

Biznis.rs

Factuality

Ownership

Novo Nordisk is considering listing its shares directly on the New York Stock Exchange, rather than having American investors trade them through depositary receipts. The company's CEO, Mike Doustdar, said that such a move has certain advantages, but emphasized that the company is currently not actively working on its implementation. The idea is being considered...

borsen.dk

Factuality

Ownership

Novo may be open to a direct listing in the US alongside its primary listing in Copenhagen instead of the current listing of so-called American Depositary Receipts (ADRs), which give US investors access to the stock, the Financial Times reports.

aripaev.ee

Factuality

Ownership

Novo CEO ready to consider swapping ADR for direct listing on US stock exchange. Shares of Danish pharmaceutical company Novo are currently available on the US market via ADR, or American Depository Receipt, but the company's CEO indicated that he is ready to consider swapping it for a direct listing. US Stock Exchange, Board of Medicines, Stock Exchange, Stock, Investing.

Dagens industri

Factuality

Ownership

Novo CEO Mike Doustdar is open to listing the Danish pharmaceutical company's shares directly on the New York Stock Exchange. "I definitely see some advantages to that," he tells the Financial Times.